Kornimate/medical-research-clean huggingface dataset:
determination of the red cell distribution width, nt-probnp and ctnt in acute myocardial infarction patients

Conditions: Myocardial Infarction

Summary: the study is to investigate the relationship of several parameters of complete blood count (cbc) including rdw with n-terminal pro-b-type natriuretic peptide (nt-probnp) and cardiac troponin t (ctnt) in a cohort of acute myocardial infarction (ami) patients.

patients and methods: * type of study: observational prospective study * place of study: sohag cardiology and gastroenterology center, department of cardiology and cardiac care unit. * ethical considerations: this research will be revised by the scientific ethical committee of sohag university hospital. consents will be taken from all patients. * study methods: * a prospective study on 30 patients diagnosed as acute myocardial infarction on which measurement of cbc, serum nt-probnp, and ctnt levels will be performed at the time of admission and by the time of discharge. 1. full history: 1. personal history: e.g. age, sex and smoking. 2. family history of cardiac diseases 3. medical history of: hypertension, ischemic heart disease, prior coronary artery bypass grafting, prior percutaneous coronary intervention, prior stroke, prior atrial fibrillation, therapeutic history 2. detailed clinical examination 3. electrocardiogram 4. laboratory investigation: 1. routine investigation in the form of cbc including rdw 2. specific investigation which include nt-probnp and ctnt

Eligibility criteria:
inclusion criteria: * patients diagnosed as acute myocardial infarction exclusion criteria: patient with * decompensated heart failure * pulmonary hypertention * acute pulmonary embolism * septic shock
effect of aerosolised colistin in ventilator associated pneumonia

Conditions: Pneumonia, Ventilator-Associated

Summary: the management of ventilator-associated pneumonia (vap) caused by multidrug-resistant (mdr) gram-negative bacilli (gnb) represent a real therapeutic dilemma in intensive care unit (icu). colistin remains an effective agent against mdr gnb. however, because of its side effects, mainly nephrotoxicity, other modalities than the intra venous (iv) route should be tried. several recent data emphasize the interest of inhaled route. the investigators purpose was to evaluate the effectiveness and systemic toxicity of aerosolized colistin in ventilator associated pneumonia.

prospective, randomized, single-blind study comparing two groups of patients treated with aerosolised (as) colistin versus colistin intravenously (iv). included were patients who have mechanical ventilation over 48 hours and that have developed a vap. a vap was defined as a cpis (clinical pulmonary infection score) \>6. exclusion criteria were septic shock and/or bacteraemia. included patients were divided into two randomized groups. the 1st received colistin in as as 4 mu by nebulisation 3 times per 24 h. the 2nd received colistin in iv as a loading dose of 9 mu followed by 4.5mu two times per 24 h. colistin was given for 14 days or until extubation. patients were followed for 28 days. therapeutic efficacy was assessed by a primary outcome: the cure of vap at day 14 of therapy and defined as resolution of clinical and biological signs of infection that means a cpis\< 6 and bacteriological eradication. secondary outcomes: duration of mechanical ventilation, icu stay-length and mortality at day 28. systemic toxicity was assessed by the occurrence of acute renal failure (arf) defined as increase of plasma creatinine more than 1.5 times its base value.

Eligibility criteria:
inclusion criteria: * critically ill patients older than 18 years, with mechanical ventilation during more than 48 hours, and who have presented a ventilator associated pneumonia (vap) defined as a cpis (clinical pulmonary infection score) of more than six exclusion criteria: * age \<18 years * pregnancy * septic shock

Keywords: colistin aerosol ventilator associated pneumonia nephrotoxicity intravenous
clinical outcome following total hip arthroplasty with the smf stem

Conditions: Joint Diseases

Summary: this is a prospective, consecutive series, multicenter clinical study of clinical outcomes following total hip arthroplasty with the smf stem.

the objectives of this study are to evaluate the safety and efficacy of the study device. this study will document any device-related, surgical or post-operative complication and adverse radiographic observations. improvement in pain, function, and health economic data will be compared with improvements documented with other joint systems. outcome measures will be quantified through statistical analysis of study device , hoos questionnaire, radiographic assessments, harris hip score, and adverse event reports.

Eligibility criteria:
inclusion criteria: * patient presents with non-inflammatory degenerative joint disease including osteoarthritis, traumatic arthritis, avascular necrosis, rheumatoid arthritis of or any of it's composite diagnosis. * patient is of legal age to consent, is skeletally mature and at least 18 years old. * patient is willing to consent to participate in the study by signing and dating an irb-approved consent form. * patient is in stable health and is free of or treated and stabilized for cardiac, pulmonary, hematological or other conditions that would pose excessive operative risk. exclusion criteria: * patient has poor bone stock and would make the procedure unjustifiable: a) patients which are under medical care for osteoporosis (taking hormones, calcitonin or biphosphates) or for other metabolic pathologies, which could influence the quality of the bone (for example hyperparathyroidism, hyperthyreoidismus and osteomalacie) will be excluded from the study. b) patients suffering from morbus paget (osteodystrophia deformans) will be excluded from the study. * patient has conditions that tend to place increased loads on implants such as weight, chargot joint, muscular deficiencies and activity level, which are incompatible with a satisfactory long-term result: a) patients with a bmi \> 40 will be excluded from the study b) patients participating in high-impact sports like baseball, basketball, football, handball, hockey, karate, racquet-ball, running, soccer, water skiing or similar impact sports will be excluded from the study. * patient is over the age of 75. * skeletal immaturity: patients must be at least 18 years at the time of the operation. * patient has an active, local infection that would lead to increased bone resorption. * mental or neurological conditions that tend to pre-empt the patient's ability or willingness to restrict activities. * known sensitivity to materials of the implant. * patient is pregnant or plans to be come pregnant during the course of the study. * patient is a prisoner.

Keywords: total hip arthroplasty total hip replacement inflammatory joint disease non-inflammatory joint disease
immune responses in hepatocellular carcinoma patients after treatment with direct acting antiviral drugs

Conditions: Drug-Induced Liver Injury

Summary: case control study to assess the difference of immune cell responses between patients with chronic hcv- related liver cirrhosis who develop hcc after treatment with daas and those who do not develop hcc

clinical and laboratory assessment with measurement of child-pugh and meld scores to assess the severity of liver disease and measurement of alpha fetoprotein level for hcc cases will be done. radiological assessment using abdominal ultrasound and triphasic ct will be done to determine the extent of the hcc and staging. blood sample from all patients will be withdrawn. plasma will be isolated and stored at - 20c and further analysis for a panel of cytokines, caspases and growth factors using elisa will be monitored. peripheral blood mononuclear cells (pbmcs) will be isolated using ficoll gradient method and will then be stored at -80c. b and t cell proliferation in response to specific antigens will also be investigated using cfse staining assay followed by flow cytometry analysis for cd4, cd8 and pd-1. cell cycle analysis and apoptosis will be detected using annexin v/pi staining method and flow cytometry analysis. the phosphorylation and activation of cytoplasmic proteins will be tested using western blot analysis.

Eligibility criteria:
inclusion criteria: * patients with hcc on top of hcv related liver cirrhosis either received treatment or not * patients without hcc either received treatment or not . * patients with chronic hcv as a control group either received treatment or not. exclusion criteria: * patients with hcc who received any interventional treatment as alcohol injection, radiofrequency , tace..etc * patients with recurrent hcc after curative treatment.

Keywords: direct acting antiviral drugs immune responses
interest in clonidine in association with levobupivacaine performing a pudendal block in proctological surgery.

Conditions: Proctological Surgery

Summary: proctological surgery represents a short duration surgery performed in ambulatory, which causes significant post-operative pain. post-operative pain resulting from proctological surgery is greater than 5 on the visual analog scale (vas) within the first 24 hours and it revives during the first defecation. the ideal pain management procedures are based on the multimodal analgesia model, based in turn on the combination of products and / or techniques to improve the quality of analgesia, reduce the side effects linked to the use of opioids, reduce responses to surgical stress, reduce postoperative recovery and allow rapid rehabilitation of the patient. the aim of our study is to investigate whether clonidine combined with levobupivacaine in the pudendal block reduce the total consumption of opioids in proctological surgery.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * signature of informed consent exclusion criteria: * refusal to participate ; * allergy to either local anaesthetics or clonidine; * local infectious pathologies (e.g. acute ano-perineal suppuration) * pregnancy * breastfeeding * severe bradyarrhythmia due to sinus node disease or second and third degree atrioventricular block * severe depressive condition * severe coronary artery disease * raynaud's disease * heart failure * obliterating thromboangiitis * epilepsy * spinal anesthesia

Keywords: post-operative pain pudendal block clonidine levobupivacaine
collection of tissue, blood, and other specimens from patients with head and neck tumors to study the causes, diagnosis, prevention and treatment of cancers

Conditions: Head and Neck Cancers

Summary: this is a protocol to collect tissues, blood, and other specimens from patients with malignant or nonmalignant diseases of the head and neck. collected specimens will be used in laboratory studies to investigate the growth, development, and transformation of normal and abnormal cells in the future.

this is a protocol to collect tissues, blood, and other specimens from patients with malignant or nonmalignant diseases of the head and neck. collected specimens will be used in laboratory studies to investigate the growth, development, and transformation of normal and abnormal cells in the future.

Eligibility criteria:
inclusion criteria: * patients with head and neck diseases are eligible if they have had tissue, serum, urine, or other specimens removed or collected for diagnostic or therapeutic purposes. * patients will be entered onto this protocol without preference for any racial or ethnic group. * patients may have received prior chemotherapy, radiation, surgical therapy, immunotherapy, or differentiation therapy. * the specimen collected must be large enough to allow conventional testing necessary for patient care, with the portion of the specimen reserved for research laboratory analysis excised from residual tissue that would otherwise have been discarded. exclusion criteria: * patients not giving informed consent will be excluded.

Keywords: heent cancers larynx thyroid sarcoma specimen analysis
dairy products with reduced sugar and blood glucose

Conditions: Blood Glucose, High; Metabolic Disease; Overweight and Obesity

Summary: dairy products represent an important food group in human nutrition as a source of calcium, protein, functional fats and low-glycaemic sugar lactose. while traditionally consumed natural milk and yogurt have low sugar content, many flavoured liquid dairy products such as chocolate milk, or fermented products such as yogurt have added sugar. our recent studies have shown that the partial reduction of added sugar in chocolate milk and yogurt is not associated with any inferior sensory characteristics such as taste and pleasantness compared to their full-sugar counterparts. the current project will investigate whether the liquid dairy products with reduced sugar content (value-added products) have any benefits on blood glucose control in humans.


Eligibility criteria:
inclusion criteria: * 19-35 y males and females, non-smokers exclusion criteria: * having any diseases, irregular menses in females, smoking (all types), taking medications known to influence blood glucose control, skipping breakfast, and having emotional, or learning problems that would affect their ability to participate in the study as required. individuals with known food allergies and lactose intolerance will be also excluded.

Keywords: sugar intake sweeteners diabetes obesity sweetened food products chocolate milk
p3 study brodalumab in treatment of moderate to severe plaque psoriasis

Conditions: Moderate to Severe Plaque Psoriasis

Summary: the purpose of this study is to assess the safety and efficacy of brodalumab at two different doses

.the purpose of this study is to assess the safety and efficacy of brodalumab at two different doses compared with placebo in participants with moderate to severe plaque psoriasis. a second purpose of this study is to assess the safety and efficacy brodalumab at two different doses compared with ustekinumab in participants with moderate to severe plaque psoriasis. a third purpose of this study is to assess the safety and efficacy of 4 maintenance regimens of brodalumab.

Eligibility criteria:
inclusion criteria: * subject has had stable moderate to severe plaque psoriasis for at least 6 months * subject has involved body surface area (bsa) ≥ 10%, pasi ≥ 12, and spga ≥ 3 at screening and at baseline exclusion criteria: * subject diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis, or other skin conditions at (eg, eczema) that would interfere with study evaluations * subject has known history of crohn's disease * subject has any other significant concurrent medical condition or laboratory abnormalities, as defined in the study protocol * subject has not stopped using certain psoriasis therapies as defined in the study protocol * subject has previously used ustekinumab or any anti-il-17 biologic therapy * subject is pregnant or breastfeeding, or planning to become pregnant while enrolled in the study * female subject is unwilling to use highly effective methods of birth control unless 2 years post-menopausal or surgically sterile

Keywords: psoriasis, brodalumab, amg 827
evaluation of efficacy of experimental gel to foam dentifrices in dental erosion

Conditions: Dental Erosion; Acid Wear

Summary: the purpose of this study is to compare and evaluate the ability of two european union (eu) regulated gel to foam toothpaste formulations versus a non-fluoride toothpaste using a modified in-situ model of dental erosion and remineralization. a positive control i.e fluoride containing toothpaste marketed in eu will also be compared to non-fluoride toothpaste.

the aim of this study is to assess the remineralization effects of two eu gel to foam toothpaste formulations with 1450 parts per million (ppm) of fluoride as sodium fluoride (naf) and 5% potassium nitrate (kno3) versus a non-fluoride (0 ppm f)/kno3 toothpaste as a negative control. the two experimental gel to foam toothpaste formulations differ in their relative dentine abrasivity (rda) values which is an in-vitro measure of a toothpaste abrasivity to the dentinal tissues. a marketed toothpaste containing naf and kno3 will serve as a positive control.

Eligibility criteria:
inclusion criteria: * general and oral health: good general health with (in the opinion of the investigator) no clinically ost and oht examinations. * oral requirements: * an intact maxillary dental arch suitable for the retention of the palatal appliance and an intact mandibular dental arch. subjects may have fixed bridges replacing missing teeth. * a gum base stimulated whole saliva flow rate ≥ 0.8 g/min and an unstimulated whole saliva flow rate ≥ 0.2 g/min. * contraception: women of childbearing potential who are, in the opinion of the investigator, practicing a reliable method of contraception. exclusion criteria: * oral health: * current active caries or periodontal disease that may compromise the study or the health of the subjects. * lesions of the oral cavity that could interfere with the study evaluations, including severe gingivitis, grossly carious lesions, periodontitis and other severe periodontal disease. * allergy/intolerance: known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients. * clinical study/experimental medication: * participation in another clinical study or receipt of an investigational drug within 30 days of the screening visit * previous participation in this study * substance abuse: recent history (within the last year) of alcohol or other substance abuse. * pregnancy: women who are pregnant or who are intending to become pregnant over the duration of the study * breast-feeding: women who are breast-feeding
a study of mericitabine in combination with boceprevir and pegasys/copegus in patients with chronic hepatitis c

Conditions: Hepatitis C, Chronic

Summary: this randomized, double-blind, multi-center, placebo-controlled, parallel-group study will evaluate the sustained virologic response and the safety of mericitabine (ro5024048) in combination with boceprevir and pegasys/copegus in patients with chronic hepatitis c infection. the anticipated time on study treatment is up to 48 weeks.


Eligibility criteria:
inclusion criteria: * adult patients, \>/=18 years of age * chronic hepatitis c infection for at least 6 months duration * hepatitis c genotype 1a or 1b * patients must have discontinued prior hepatitis c treatment at least 12 weeks prior to enrollment in this study * patient showed a previous null response to therapy as defined by \< 2 log10 iu/ml decrease in viral titer after at least 12 weeks of treatment with peg-ifn/rbv exclusion criteria: * hepatitis c infection with a genotype other than genotype 1a or 1b * body mass index \ /=36 * hepatitis a, hepatitis b, or hiv infection * herbal remedies \</=1 month prior to the first dose of study drug
reconstruction of the carotid bifurcation in patients with arterial hypertension of 2-3 degrees

Conditions: Hypertension; Carotid Stenosis; Symptomatic Carotid Artery Stenosis

Summary: carotid endarterectomy (cea) is a well-established procedure for preventing ischemic brain damage. stenosis of the precerebral vessels are often combined with arterial hypertension. in recent decades, many works have appeared that indicate that the course of arterial hypertension (ah) changes after cea. however, it remains unknown how this is related to the choice of surgical tactics.

purpose of the study: to substantiate the choice of the method of surgical treatment in patients with a combination of hemodynamically significant stenosis of the carotid bifurcation and arterial hypertension of 2-3 degrees. tasks: 1. to study the course of hypertension after carotid endarterectomy with removal of the carotid glomus. 2. to study the course of hypertension in patients after stenting of the internal carotid artery. 3. to substantiate the strategy for performing carotid endarterectomy in patients with bilateral significant lesions of the internal carotid artery. 4. to substantiate the choice of a surgical treatment strategy in patients with significant stenosis of the carotid bifurcation and 2-3 degree of hypertension. methods for examining patients: collection of complaints and anamnesis, objective examination, questioning of patients, instrumental examination (ultrasound of bcs, daily monitoring of blood pressure, ct of the brain, cerebral angiography). as a result of the study, the optimal tactics of surgical treatment in patients with carotid artery stenosis and the presence of hypertension will be determined.

Eligibility criteria:
inclusion criteria: * presence of symptomatic ica stenosis 70-90% * arterial hypertension of 2 or 3 degrees * cea operation with carotid glomus removal or ica stenting operation exclusion criteria: * severe diabetes * traumatic brain injury in history * ihd, stable angina pectoris 3-4 fc. * presence of clinical signs of vertebrobasilar insufficiency * the presence of significant stenosis of the renal arteries * ckd stages 3b-5

Keywords: hypertension carotid stenosis symptomatic carotid artery stenosis glomus ectomy carotid endarterectomy carotid stenting
gt101 injection in the treatment of metastatic/recurrent advanced solid tumors

Conditions: Adult

Summary: this study is a single center, single arm phase i clinical trial. this study proposes to enroll 20 subjects, with a trial protocol including chemotherapy pretreatment, reinfusion of autologous tumor infiltrating lymphocyte injection, and interleukin-2 injection.


Eligibility criteria:
inclusion criteria: * 1. the patients (or legally authorized representative) patients (or legally authorized representative) must have the ability to understand the requirements of the study, have provided written informed consent as evidenced by signature on an informed consent form (icf) approved by an institutional review board/independent ethics committee (irb/iec), must have the ability to understand the requirements of the study; * 2.must have a confirmed diagnosis of malignancy of their receptive histologies or cytologies: unresectable recurrent or metastatic solid tumor; * 3.at least one resectable lesion (preferably superficial metastatic lymph nodes) that has not been treated with radiation and has not received other local therapies. the separated tissues mass volume ≥1cm\^3 (either of single lesion origin or multiple lesions combined) for the preparation of autologous tumor-infiltrating lymphocytes. minimally invasive treatment where possible; exclusion criteria: * 1. patients who have symptomatic and/or untreated cns metastases (except stable brain metastases, no medication required within 3 months, no hormone dependence); * 2.active infections requiring treatment with systemic anti-infectives (except for topical antibiotics); or those with unexplained fever \> 38.5℃ occurring during the screening period, except for tumor fever; * 3. patients who have refractory or intractable epilepsy, active gastrointestinal bleeding or il-2 contraindications; * 4. patients who have received allogeneic bone marrow transplantation or an organ allograft; * 5.patients who have a history of hypersensitivity to any component or excipient of study drugs: autologous tumor infiltrating lymphocytes, cyclophosphamide, fludarabine, il-2, dimethyl sulfoxide (dmso), human serum albumin (hsa), dextran-40 and antibiotics (beta lactam antibiotics, gentamicin);